Stallergenes has been granted European approval to market Oralair in both adults and children through a Mutual Recognition Procedure. Oralair is an immunotherapy tablet aimed at patients suffering
EMEA has validated ChemGenex Pharmaceuticals’ (ChemGenex) Marketing Authorisation Application (MAA) for omacetaxine mepesuccinate for the treatment of chronic myeloid leukemia (CML) patients who have failed treatment with imatinib
The FDA has approved Agriflu for people ages 18 years and older to prevent disease caused by influenza virus subtypes A and B. Agriflu, manufactured by Novartis Vaccines
Boehringer Ingelheim has reported that the European Commission has approved Micardis (telmisartan) for the reduction of cardiovascular morbidity in patients with manifest atherothrombotic cardiovascular disease or type 2
Boehringer Ingelheim has concluded its collaboration with Vectura by mutual consent. Under the terms of the agreement, signed in April 2006, Boehringer Ingelheim has worked with Vectura to
Merck & Co., through an affiliate, has extended its research collaboration with Idera for a fourth year. In December 2006, the companies entered into an exclusive license and
Pfizer Japan (Pfizer) and Astellas Pharma (Astellas) to launch the combination drug of hypertension treatment and hypercholesterolemia treatment Caduet combination tablets (generic name: amlodipine besylate and atorvastatin calcium)
The FDA has granted traditional approval for Tibotec Therapeutics’ Intelence (etravirine) tablets, a non-nucleoside reverse transcriptase inhibitor (NNRTI). Intelence is currently marketed in the US by Tibotec, a
Glycotope has received regulatory approval by Germany and Italian regulatory authorities for a Phase I study of Glycotope’s lead antibody GT-MAB 2.5-GEX for the treatment of various solid
Takeda has submitted a supplemental new drug application to the Ministry of Health, Welfare and Labour in Japan for Takepron Capsules 15 and Takepron OD tablet 15 (lansoprazole)
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.